$2.63
-0.18 (-6.41%)
Open$2.79
Previous Close$2.81
Day High$2.79
Day Low$2.62
52W High$12.30
52W Low$2.30
Volume—
Avg Volume310.2K
Market Cap8.96M
P/E Ratio—
EPS$-6.72
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+952.9% upside
Current
$2.63
$2.63
Target
$27.69
$27.69
$21.92
$27.69 avg
$40.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.21M | 2.22M | 3.54M |
| Net Income | -41,777,288 | -37,837,938 | -86,327 |
| Profit Margin | -1,893.6% | -1,798.9% | -2.4% |
| EBITDA | -40,592,264 | -38,807,135 | -134,724 |
| Free Cash Flow | — | — | -61,141 |
| Rev Growth | -0.6% | -0.6% | +8.8% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |